Drugs / APVO436
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04973618 | Jan 2025 → Jan 2026 | acute myeloid leukemia | Aptevo Therapeutics | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06634394 | Oct 2024 → Oct 2027 expected | acute myeloid leukemia | Aptevo Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT03647800 | Dec 2018 → Dec 2022 | acute myeloid leukemia, myelodysplastic syndrome | Aptevo Research and Development LLC | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APVO436 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06634394 ↗ |
| Action | Deplete | “designed to redirect host T cell cytotoxicity in an MHC-independent manner to CD123-expressing blast cells” PMID 34439266 ↗ Aug 2021 |
| Modality | Monoclonal antibody | “CD123 and CD3 epsilon bispecific antibody” NCT04973618 ↗ |
| Route | Intravenous | “APVO436 administered intravenously to patients with AML or MDS” NCT03647800 ↗ |